Applicant : Vladimir BAKHUTASHVILI

U.S. Serial No.: 10/795,819 Filing Date : March 8, 2004

Page : 2

AMENDMENTS TO THE CLAIMS:

Claims 1, 4-22, 25-64, 66 and 68-84 were previously canceled without prejudice. Applicant adds new claims 85-98.

- 1. (Canceled)
- 2. (Currently Amended) A composition with apoptosis modulating activity obtainable from human or animal amniotic tissue products or tissue prepared according to a method comprising the steps of: priming, induction, biosynthesis, and purification of the product.
- 3. (Original) A composition of claim 2 including lyophilizing the product.

4-22. (Canceled)

- 23. (Original) A method for improving the skin condition of a subject comprising contacting an effective amount of a composition with anti-apoptotic, anti-wrinkle, anti-aging, or anti-drying activity obtainable from human amniotic tissue with said skin surface on the subject.
- 24. (Original) A method of claim 23 wherein the composition with anti-apoptotic, anti-wrinkle, anti-aging, or antidrying activity is prepared from chemical formulation, genetic engineering or synthesis.

25-64. (Canceled)

- 65. (Original) A composition with apoptosis modulating activity obtainable from human amniotic tissue having characteristic peaks as set forth in Figure 3.
- 66. (Canceled)

Applicant : Vladimir BAKHUTASHVILI

U.S. Serial No.: 10/795,819 Filing Date : March 8, 2004

Page : 3

67. (Original) A method for protecting cardiomyocytes from injury, comprising contacting said cardiomyocytes with an effective amount of the composition of claim 65.

68-84. (Canceled)

Please add the following new claims:

- 85. (New) The composition according to claim 2, further comprising a pharmaceutically effective agent.
- 86. (New) The composition according to claim 85, wherein the agent is selected from the group consisting antibiotics, wound healing agents, antioxidants, antivirals, antifungals, anti-ischemics, anti-injury, and anti-aging, immunomodulatory, anti-hypoxic, anti-toxic, anti-wrinkle, anti-inflammatory, anti-allergic, infectious, anti-immunogenic, and anti-neoplastic.
- 87. (New) The composition according to claim 2, further comprising a physiologically acceptable carrier.
- 88. (New) The composition according to claim 87 wherein the carrier is suitable for topical administration, for parenteral administration, or for gastrointestinal administration.
- 89. (New) A composition with apoptosis modulating activity obtainable from human amniotic tissue having characteristic peaks as set forth in Figure 2.
- 90. (New) A composition with apoptosis modulating activity obtainable from human amniotic tissue having at least one characteristic peak as set forth in Figure 2.
- 91. (New) A composition with apoptosis modulating activity obtainable from human amniotic tissue having at least one characteristic peak as set forth in Figure 3.

Applicant : Vladimir BAKHUTASHVILI

U.S. Serial No.: 10/795,819 Filing Date : March 8, 2004

Page : 4

92. (New) A composition capable of inhibiting or killing cancer cells, wherein said composition is obtainable from human amniotic tissue with apoptosis modulating activity.

- 93. (New) A composition which is antagonistic to H1-histamine receptor, wherein said composition is obtainable from human amniotic tissue with apoptosis modulating activity.
- 94. (New) A composition which is inhibitory to A2-phospholipase activity, wherein said composition is obtainable from human amniotic tissue with apoptosis modulating activity.
- 95. (New) A composition for protecting cardiomyocytes, wherein said composition is obtainable from human amniotic tissue with apoptosis modulating activity.
- 96. (New) A composition for protecting against the effects of Tumor Necrosis Factor (TNF), wherein said composition is obtainable from human amniotic tissue with apoptosis modulating activity.
- 97. (New) A method for protecting cardiomyocytes cells comprising contacting said cardiomyocytes with the composition of claim 2.
- 98. (New) A method for improving the skin condition of a subject comprising contacting said skin with the composition of claim 2.

5